Rose Sharon Shabet's Net Worth
$0
Who is Rose Sharon Shabet?
Rose Sharon Shabet does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Amylyx Pharmaceuticals, Inc., Adaptive Biotechnologies Corp, Zentalis Pharmaceuticals, LLC, RayzeBio, Inc., Inhibrx, Inc., Arbutus Biopharma Corp, Myovant Sciences Ltd., Roivant Sciences Ltd., PROCEPT BioRobotics Corp, BridgeBio Pharma, Inc., 4D Molecular Therapeutics, Inc., Ginkgo Bioworks Holdings, Inc., APi Group Corp, FIGS, Inc., Urovant Sciences Ltd., Axovant Sciences Ltd., Rallybio Corp, Frazier Lifesciences Acquisition Corp, STANDARD BIOTOOLS INC., and Inhibrx Biosciences, Inc..
SEC CIK
Rose Sharon Shabet's CIK is 0001711393
Past Insider Trading and Trends
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Amylyx Pharmaceuticals, Inc. (AMLX) Snapshot price: $2.37
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -10.26% | -1.40M |
$29.80 | -$41,719,639.31 | 12.24M |
Sep 8 - Sep 9
| |||
Form 4
|
∞
| 7.17M |
$19.00 | $43,700,000.00 | 7.17M |
Jan 11 - Nov 11
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Adaptive Biotechnologies Corp (ADPT) Snapshot price: $4.21
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -3.23% | -1.00M |
$55.65 | -$55,650,000.00 | 29.99M |
Dec 14
| |||
Form 4
| -7.46% | -2.50M |
$49.52 | -$123,787,500.00 | 30.99M |
Nov 11
| |||
Form 4
| -7.46% | -2.50M |
$49.52 | -$123,787,500.00 | 30.99M |
Nov 11
| |||
Form 4
| -12.79% | -4.91M |
$24.98 | -$122,706,039.29 | 33.49M |
Jan 28
| |||
Form 4
| -12.79% | -4.91M |
$24.98 | -$122,706,039.29 | 33.49M |
Jan 28
| |||
Form 4
| +2,595.20% | 36.98M |
$20.00 |
—
| 38.41M |
Jul 1
| |||
Form 4
| +2,595.20% | 36.98M |
$20.00 |
—
| 38.41M |
Jul 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Zentalis Pharmaceuticals, Inc. (ZNTL) Snapshot price: $2.96
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -11.25% | -500.00K |
$50.50 | -$25,250,000.00 | 3.94M |
Dec 1
| |||
Form 4
| +19.50% | 725K |
$18.00 | $13,050,000.00 | 4.44M |
Apr 7
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
RayzeBio, Inc. (RYZB) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -6.64M |
—
|
—
|
0
|
Feb 26
| |||
Form 4
| -100.00% | -6.64M |
—
|
—
|
0
|
Feb 26
| |||
Form 4
|
∞
| 6.64M |
$18.00 |
—
| 6.64M |
Sep 19
| |||
Form 4
|
∞
| 6.64M |
$18.00 |
—
| 6.64M |
Sep 19
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Inhibrx, Inc. (INBX) Snapshot price: $15.06
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -7.15M |
$30.00 | -$214,524,780.00 |
0
|
May 30
| |||
Form 4
|
∞
| 511.63K |
$19.35 | $9,899,982.45 | 511.63K |
Aug 28
| |||
Form 4
| +93.42% | 1.33M |
$30.00 | $39,999,856.67 | 2.76M |
Oct 7
| |||
Form 4
| +14.45% | 180.22K |
$18.92 | $3,409,865.52 | 1.43M |
Aug 26
| |||
Form 4
| +11.78% | 131.47K |
$19.39 | $2,548,687.94 | 1.25M |
Aug 24 - Aug 25
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||